Albert David: Should You Buy, Hold, or Sell Right Now?

Albert David share price Rs 860.70 (NSE), well off its 52-week high. 52-week range Rs 579.90 to Rs 931.85. Trailing return on equity of -0.38%.

Updated: 4 Sept 2026 • 5:17 pm

Posted by:

Albert David: Should You Buy, Hold, or Sell Right Now?

Quick Answer

Albert David Ltd share price is trading around Rs 861, roughly 8 percent below its 52-week high of Rs 931.85 but well above its 52-week low of Rs 579.90. This pharmaceutical formulations manufacturer trades at a price to earnings ratio of 21.95, a discount to the pharma sector average near 51.2 times, with a trailing return on equity of -0.38 percent and a book value per share of Rs 685.71. Current-quarter financial data was not consistently available across public sources at the time of writing, so this article relies on the most recently available trailing metrics and urges appropriate caution given the near-breakeven trailing position.

Albert David share price is trading around Rs 861 on the NSE, roughly 8 percent below its 52-week high of Rs 931.85, well above its 52-week low of Rs 579.90. Given the near-breakeven trailing earnings position and limited current-quarter data, this article presents the available valuation picture plainly before laying out a balanced view.

This Albert David overview walks through the available valuation data, the discount to the pharma sector, shareholding pattern and the technical setup, using figures sourced from public filings, with appropriate caveats given the data limitations involved.

Click Here – Get Free Investment Predictions

Table of Contents

About Albert David

Before deciding on Albert David share price, it helps to understand the underlying business. Albert David Ltd. manufactures pharmaceutical formulations, serving both domestic and export markets with a range of branded and generic medicines.

As a pharmaceutical formulations manufacturer, Albert David's trailing results show the business operating close to breakeven, and current-quarter data was not consistently available across public sources at the time of writing, meaning investors should seek the company's latest exchange filings directly for more current information.

Albert David Share Price Today: Key Levels

The table below summarises where Albert David share price stands right now against its recent trading range and market value.

Metric	Value
Albert David CMP (NSE)	Rs 860.70
Albert David CMP (BSE)	Rs 862.00
52-Week High	Rs 931.85
52-Week Low	Rs 579.90
Market Capitalisation	Approximately Rs 495 crore

Albert David share price is trading well above its 52-week low, close to its 52-week high, even as the company's trailing earnings remain close to breakeven.

Check the Univest Screener for Live Stock Data

Albert David Financial Performance

The Albert David share price trend is closely tied to how these numbers evolve each quarter. Current-quarter financial data for Albert David was not consistently available across public sources at the time of writing. The company's trailing twelve-month figures show a positive EPS of Rs 39.52 alongside a return on equity of -0.38 percent, a combination that suggests recent quarterly volatility around a roughly breakeven trend.

Investors should refer directly to the company's latest exchange filings for updated quarterly figures before drawing conclusions about the current trend, given the limited publicly available recent data.

Period	Revenue	Net Profit	Comment
Trailing twelve months	Not fully disclosed publicly	EPS Rs 39.52, ROE -0.38%	Current-quarter data not consistently available

Valuation Check: Is Albert David Share Price Expensive?

Any view on Albert David share price should start from these valuation multiples. Albert David share price currently reflects a price to earnings ratio of about 21.95 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 51.2 times. The price to book ratio stands at 1.27 times, with a dividend yield of 0.58 percent.

Debt to equity of 0.08 is very low. Given the near-breakeven trailing return on equity, this discount to the pharma sector likely reflects the market's assessment of the company's currently modest profitability relative to larger, more consistently profitable pharmaceutical peers.

Technical Signals: What the Chart Shows

Price action here often foreshadows the next move in Albert David share price. Albert David share price is currently positioned roughly 8 percent below its 52-week high of Rs 931.85 and well above its 52-week low of Rs 579.90, reflecting a fairly strong overall position within its annual trading range. Given the limited current-quarter data available, investors should track Albert David share price alongside the company's next confirmed quarterly disclosure for clearer signals.

Trading volumes remain light, so investors should watch for the company's next earnings announcement to better understand the current trend, rather than relying solely on trailing valuation metrics at these technical levels.

Download the Univest iOS App or Univest Android App to track Albert David's live price and technical levels.

Shareholding Pattern

Shifts here can influence Albert David share price more than headline news on some sessions. Albert David is a promoter-led pharmaceutical formulations manufacturer. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company's latest exchange filing.

Why Investors Are Watching Albert David

Discount valuation to sector: A 21.95x PE against a 51.2x pharmaceutical sector average offers meaningful valuation cushion.
Very low financial leverage: A debt to equity ratio of just 0.08 gives the company significant financial flexibility.
Stock well above its 52-week low: Trading roughly 8 percent below its 52-week high, the stock has held up reasonably well over the past year.

Risks and Factors to Watch

Near-breakeven trailing earnings: A trailing return on equity of -0.38 percent indicates the business is currently generating minimal or negative returns for shareholders on a trailing basis.
Limited current-quarter data: Recent quarterly financial data was not consistently available across public sources at the time of writing, creating an information gap for investors.
Pharmaceutical formulations competitive market: Albert David competes against numerous domestic and international pharmaceutical formulations manufacturers.
Small-cap liquidity risk: As a smaller-cap pharmaceutical stock with a market capitalisation of approximately Rs 495 crore, trading liquidity can be more limited than larger peers.

Albert David Share Price Target: What the Data Suggests

Until then, Albert David share price remains best tracked through live, verified data rather than a single fixed number. Albert David does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the limited current-quarter data available.

Investors considering this stock should track the Univest Screener for the company's next confirmed quarterly disclosure, and should consult a SEBI-registered investment adviser given the near-breakeven trailing position.

Albert David: Should You Buy, Hold, or Sell Right Now?

This is the core question behind Albert David share price right now. The Albert David buy or sell decision should account for the limited current-quarter data and near-breakeven trailing position.

The case for buying: Value-focused investors who see the discount to the pharma sector as attractive, and who are comfortable proceeding with the most recently available data, may find the current level worth considering.

The case for holding: Existing shareholders who already track Albert David's pharmaceutical formulations business may prefer to stay invested.

The case for waiting: Investors wanting more current quarterly confirmation before committing fresh capital may prefer to wait for the company's next earnings disclosure.

Given the data limitations here, weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.

Conclusion

Albert David share price reflects a pharmaceutical formulations manufacturer trading at a discount to the broader pharma sector, with trailing earnings close to breakeven and limited current-quarter data available. This article is for informational purposes and not a personalised investment recommendation.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Q1. Is Albert David a good stock to buy right now?

Ans. Albert David trades at a discount of 21.95 times earnings against a 51.2 times pharma sector average, though trailing return on equity is close to breakeven at -0.38 percent. Given the limited current-quarter data, this suits value-focused investors comfortable proceeding with the most recently available figures.

Q2. What is the Albert David share price today?

Ans. Albert David share price is trading around Rs 861 on the NSE. The stock's 52-week high is Rs 931.85 and its 52-week low is Rs 579.90.

Q3. What is the Albert David share price target?

Ans. Albert David does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the limited current-quarter data.

Q4. What does Albert David manufacture?

Ans. Albert David manufactures pharmaceutical formulations, serving both domestic and export markets with branded and generic medicines.

Q5. What is Albert David's market capitalisation and PE ratio?

Ans. Albert David has a market capitalisation of approximately Rs 495 crore and trades at a price to earnings ratio of about 21.95 times, a discount to the pharmaceutical sector average PE of roughly 51.2 times.